Bishop AL, Hall A (2000) Rho GTPases and their effector proteins. Biochem J 348(2):241–255

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119(1):182–192

PubMed  CAS  Google Scholar 

Cookson MR (2005) The biochemistry of Parkinson’s disease. Annu Rev Biochem 74(1):29–52

Article  PubMed  CAS  Google Scholar 

He Q, Li Y, Guo S, Wang Y, Lin W, Zhang Q, CungenMa BaoguoXiao (2016) Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson’s model. Eur J Neurosci 43(1):41–52

Article  PubMed  Google Scholar 

Kahles T, Luedike P, Endres M, Galla H-J, Steinmetz H, Busse R, NeumannHaefelin T, Brandes RP (2007) NADPH oxidase plays a central role in bloodbrain barrier damage in experimental stroke. Stroke 38:3000–3006

Article  PubMed  CAS  Google Scholar 

Krack P et al (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349:1925–1934

Article  PubMed  CAS  Google Scholar 

Lograsso PV, Feng Y (2009) Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 9(8):704–723

Article  PubMed  CAS  Google Scholar 

Loirand G (2015) Rho Kinases in Health and Disease: From Basic Science to Translational Research. Pharmacol Rev 67(4):1074–1095

Article  PubMed  CAS  Google Scholar 

Meissner W, Hill MP, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25:249–253

Article  PubMed  CAS  Google Scholar 

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175

Article  PubMed  CAS  Google Scholar 

Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744–1754

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schmitz AA, Govek EE, Böttner B, Van Aelst L (2000) Rho GTPases: signaling, migration, and invasion. Exp Cell Res. 261(1):1–12

Article  PubMed  CAS  Google Scholar 

Schofield AV, Bernard O (2013) Rho-associated coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem Mol Biol 48(4):301–316

Article  PubMed  CAS  Google Scholar 

Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K (2007) A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 68:126–131

Article  PubMed  Google Scholar 

Tatenhorst L, Eckermann K, Dambeck V, Fonsecaornelas L, Walle H, Fonseca TLD, Koch JC, Becker S, Tonges L, Bahr M, Outeiro TF, Zweckstetter M, Lingor P (2016) Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease. Acta Neuropathol Commun 4:39

Article  PubMed  PubMed Central  Google Scholar 

Tong Chen Lu, Xiao LZ, Ma S, Yan T, Ji H (2015) Anti-Asthmatic Effects of Ginsenoside Rb1 in a Mouse Model of Allergic Asthma Through Relegating Th1/Th2. Inflammation 38(5):1814–1821

Article  PubMed  Google Scholar 

Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL (2012) Involvement of microglial RhoA/RhoKinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 47:268–279

Article  PubMed  CAS  Google Scholar 

Voon V et al (2009) Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol 8:1140–1149

Article  PubMed  CAS  Google Scholar 

Wassilios G, Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10(5):377–393

Article  Google Scholar 

Watzlawick R, Sena ES, Dirnagl U, Brommer B, Kopp MA, Macleod MR, Howells DW, Schwab JM (2014) Effect and reporting bias of RhoA/ROCK-blockade intervention on locomotor recovery after spinal cord injury: a systematic review and meta-analysis. JAMA Neurol. 71:91–99

Article  PubMed  Google Scholar 

Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol 150:963–976

Article  PubMed  PubMed Central  CAS  Google Scholar 

Whitton PS (2009) Inflammation as a causative factor in the aetiology of Parkinson’s disease: Inflammation and Parkinson’s disease. Br J Pharmacol 150(8):963–976

Article  Google Scholar 

Wu J, Li J, Hu H, Liu P, Fang Y, Wu D (2012) Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol 32:1187–1197

Article  PubMed  CAS  Google Scholar 

Zhu L, Chen T, Chang X, Zhou R, Luo F, Liu J, Zhang K, Wang Y, Yang Y, Long H, Liu Y (2016) Salidroside ameliorates arthritis-induced brain cognition deficits by regulating Rho/ROCK/NF-kB pathway. Neuropharmacology 103:134–142

Article  PubMed  CAS  Google Scholar